enter passkey to continue
incorrect passkey
Sequence LAL is a physician-designed clinical program for the systematic identification, diagnosis, and longitudinal management of patients across the full LAL deficiency spectrum — from infantile Wolman disease through adult-onset CESD — grounded in Phase 3 trial data, international registry evidence, and structured around validated clinical endpoints.
Lysosomal acid lipase deficiency presents with a phenotype that overlaps common conditions — NAFLD/NASH, familial hypercholesterolemia, and cryptogenic cirrhosis — leading to years of diagnostic delay and misattributed treatment. The diagnostic signal is hiding in plain sight: statin-resistant dyslipidemia with unexplained liver disease.
International registry data from 228 patients reveals a median diagnostic delay of 3.3 years from symptom onset to confirmed diagnosis. Carrier frequency is estimated at 1:500 in European populations, with disease frequency ranging from 1:40,000 to 1:300,000. Most patients cycle through hepatology and lipid clinics without identification.
Registry data shows 47% of patients with lobular inflammation on biopsy, 37% with bridging fibrosis, and 14% with cirrhosis at presentation. Without diagnosis, these patients receive standard hepatology management while the underlying lysosomal storage continues unchecked, with fibrosis advancing toward decompensation.
LAL activity is reduced even in non-genetic NAFLD, creating a diagnostic gray zone. Non-obese patients with hepatic steatosis, elevated transaminases, and dyslipidemia represent a high-yield screening population. A simple dried blood spot test can confirm or exclude LAL-D and should be ordered before liver biopsy in suspected cases.
Patients with elevated LDL, low HDL, raised transaminases, and poor response to statin therapy should have LAL enzyme activity measured via dried blood spot. This combination — particularly in non-obese individuals — is the cardinal presentation of late-onset LAL deficiency.
LAL deficiency encompasses two OMIM entries — Wolman disease and cholesteryl ester storage disease — representing severe and attenuated ends of a single genetic continuum, with clinical phenotype determined by residual LAL enzyme activity.
Onset 1-3 months. Massive hepatosplenomegaly, failure to thrive, adrenal calcification (~67%), vomiting, diarrhea, malabsorption. Without treatment: near-100% mortality by 6-12 months.
Childhood to adult onset. Hepatomegaly, steatosis → fibrosis/cirrhosis, dyslipidemia (↑LDL, ↓HDL, ↑TG), accelerated atherosclerosis. E8SJM splice variant accounts for 50-70% of late-onset alleles.
LIPA (10q23.31, 10 exons) encodes lysosomal acid lipase, the enzyme responsible for hydrolyzing cholesteryl esters and triglycerides within lysosomes. The E8SJM variant (c.894G>A) at the exon 8 splice junction allows a small amount of normally spliced mRNA — producing the residual enzyme activity that distinguishes CESD from Wolman disease. Among 157 registry patients with reported mutations, 70 were homozygous and 45 compound heterozygous for E8SJM.
This structured clinical pathway maps each phase to specific evidence citations from Phase 3 trial data (ARISE, VITAL, CL08), 10-year longitudinal follow-up studies, and international LAL-D registry evidence from 228 patients.
Clinical assessment and DBS LAL enzyme activity testing (Lalistat2 fluorimetric assay, 5-10 day turnaround). LIPA gene sequencing for molecular confirmation. Genotype results, liver biopsy or FibroScan for fibrosis staging, baseline abdominal imaging, lipid panel (LDL, HDL, TG), hepatic function (ALT, AST, GGT, bilirubin), and comprehensive metabolic panel. Differential diagnosis excludes NAFLD/NASH, FH, Wilson disease, alpha-1 antitrypsin deficiency, and Niemann-Pick type C.
First sebelipase alfa infusion (1 mg/kg IV q2w for CESD; 1 mg/kg IV q1w for Wolman with escalation to 3 mg/kg as needed). Pre-medication assessment, infusion tolerance monitoring, baseline nutritional evaluation, dietary counseling (low-fat, MCT-supplemented, fat-soluble vitamin optimization), and early laboratory tracking to establish treatment trajectory.
Dose optimization based on treatment response. Serial monitoring: 3-month labs (ALT/AST, lipid panel, CBC), growth assessment (pediatric), and 6-month imaging with FibroScan/elastography. Phase gate review confirms biochemical improvement (target: ALT normalization or >50% reduction, LDL >20% reduction, HDL >15% increase) before transition to maintenance.
Continued q2w infusions (CESD) or q1w (Wolman) with quarterly labs (lipids, LFTs, CBC), biannual abdominal imaging and elastography, infusion tolerance tracking, nutrition review, and long-term monitoring of hepatic fibrosis stabilization, lipid control, and growth velocity in children. Phase 3 ARISE data shows sustained improvement through 144 weeks.
Full annual review: comprehensive metabolic panel, liver imaging with elastography, cardiovascular risk assessment (carotid IMT, coronary calcium scoring in adults), bone density, ophthalmologic exam (corneal arcus), quality of life measures (EQ-5D-5L, SF-36/PedsQL), developmental assessment (pediatric), and liver biopsy consideration every 2-3 years if fibrosis present.
Diagnosis follows a tiered approach: clinical suspicion triggers DBS enzyme testing, followed by molecular confirmation and comprehensive staging. The diagnostic algorithm is grounded in international consensus recommendations and validated across the global LAL-D registry.
Sebelipase alfa is FDA/EMA-approved across all ages. Treatment decisions are stratified by disease severity, with defined response markers and escalation criteria derived from the ARISE Phase 3 trial and 10-year longitudinal follow-up data.
Biochemical response expected by 3-6 months: ALT/AST normalization or >50% reduction, LDL >20% reduction, HDL >15% increase, triglyceride improvement. Imaging response by 6-12 months: liver and spleen volume reduction, hepatic steatosis improvement, catch-up growth (pediatric). Long-term by 12-24 months: FibroScan stabilization or improvement, with fibrosis regression (F4→F1-2) reported with sustained ERT.
HSCT remains second-line for Wolman disease when ERT is insufficient (EBMT Inborn Errors Working Party data). Liver transplantation provides excellent hepatic correction with 8-year disease-free survival reported, but does not correct systemic enzyme deficiency. Supportive measures include low-fat diets, MCT supplementation, fat-soluble vitamins, and cardiovascular risk management. Emerging therapies — mRNA-based hepatic LAL restoration and AAV-mediated gene therapy — are in preclinical development with no human trials as of 2025.
The outcomes framework is designed around instruments validated in LAL-D clinical trials and recommended for longitudinal monitoring. Every patient encounter generates structured, analyzable endpoint data across the full disease spectrum.
| Instrument | Domain | Clinical Endpoint | Schedule |
|---|---|---|---|
| PedsQL 4.0 | Generic HRQoL (Pediatric) | Health-related quality of life, ages 2-18 | q6m |
| PedsQL Infant Scales | Generic HRQoL (Infant) | Wolman disease monitoring, ages 1-24 months | q3m |
| PedsQL GI Module | Gastrointestinal | GI symptom burden, malabsorption tracking | q6m |
| SF-36 | Generic HRQoL (Adult) | Physical and mental health composite, ages 18+ | q12m |
| EQ-5D-5L | Quality of Life | Utility measure for health economics | q12m |
| CLDQ | Liver-Specific QoL | Chronic Liver Disease Questionnaire; fatigue red flag <4.0 | q12m |
| PedsQL Fatigue | Fatigue (Pediatric) | Multidimensional fatigue scale, ages 5-18 | q6m |
| PROMIS Fatigue | Fatigue (Adult) | Fatigue severity and impact | q6m |
| PROMIS GI Symptoms | Gastrointestinal (Adult) | GI symptom burden and functional impact | q6m |
| Growth Diary | Nutritional (Infant/Child) | Weight, length, head circumference trajectories | continuous |
All PROM data, biochemical results (lipids, LFTs, CBC), imaging endpoints (liver volume, elastography, adrenal imaging), treatment milestones, and infusion records are captured in a structured longitudinal database with automated red-flag detection, treatment response tracking, and population-level analytics. This infrastructure enables real-world evidence generation, ERT response monitoring, and natural history characterization across both the Wolman and CESD populations.
Comprehensive LAL deficiency management requires coordinated expertise across multiple specialties. This program provides the organizational infrastructure for a structured multidisciplinary model spanning the full disease spectrum.
Disease state management, LIPA variant interpretation, treatment decision-making, and longitudinal care coordination. The clinical geneticist serves as the program anchor across both infantile and adult populations.
Pre- and post-test LIPA counseling, family cascade testing coordination, carrier identification, reproductive planning, and autosomal recessive inheritance education for affected families.
Liver disease staging and co-management, fibrosis monitoring (FibroScan, biopsy), cirrhosis management, portal hypertension surveillance, and liver transplantation evaluation for refractory cases.
Dyslipidemia management complementary to ERT, cardiovascular risk stratification, statin co-therapy optimization, and atherosclerosis monitoring via carotid IMT and coronary calcium scoring.
Fat-restricted dietary management, MCT supplementation, fat-soluble vitamin optimization (A, D, E, K), growth monitoring in pediatric patients, and parenteral nutrition planning for severe Wolman cases.
Cardiovascular risk management for CESD patients with accelerated atherosclerosis. Neonatology and pediatric GI co-management for infantile Wolman disease. Infusion coordination and tolerance monitoring.
Sequence LAL was designed for patients and families living with lysosomal acid lipase deficiency — providing the structured, evidence-based clinical framework that LAL-D care has been missing.
LAL deficiency care today is fragmented across hepatology, lipidology, and primary care — none of whom own the diagnosis. With a median 3.3-year diagnostic delay and only 228 patients in the global registry, most affected individuals remain unidentified. This program provides the missing organizational layer: a single clinical home where identification, diagnosis, treatment decision-making, and longitudinal monitoring follow a structured, evidence-based protocol across the full disease spectrum.
Rather than ad hoc management, Sequence LAL builds the clinical infrastructure for systematic LAL-D care: standardized diagnostic workflows (DBS → LIPA sequencing → staging), structured treatment initiation protocols stratified by disease severity, validated outcomes collection at every encounter, multidisciplinary coordination across hepatology, lipidology, genetics, and nutrition, and a longitudinal data architecture designed for real-world evidence generation.